WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.

4512 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Wakamoto Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and sale of prescription (ethical) and over-the-counter (OTC) medicines. The company specializes in two primary therapeutic areas: gastroenterology and ophthalmology. Its product portfolio includes the well-known gastrointestinal drug "Strong Wakamoto," which utilizes a proprietary microorganism to produce digestive enzymes, and a range of ophthalmic solutions for treating eye disorders. Wakamoto Pharmaceutical focuses its research and development efforts on creating medications and medical equipment to address the health challenges of an aging society.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for WAKAMOTO PHARMACEUTICAL CO.,LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-27 10:03
Post-Annual General Meeting Information
臨時報告書
Japanese 24.7 KB
2025-06-20 08:53
Governance Information
内部統制報告書-第130期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:51
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:48
Annual Report
有価証券報告書-第130期(2024/04/01-2025/03/31)
Japanese 1014.1 KB
2025-02-06 08:28
Major Shareholding Notification
臨時報告書
Japanese 19.3 KB
2024-11-13 01:51
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-13 01:46
Interim Report
半期報告書-第130期(2024/04/01-2025/03/31)
Japanese 183.5 KB
2024-07-02 05:00
Regulatory News Service
臨時報告書
Japanese 33.6 KB
2024-06-28 08:24
Regulatory News Service
内部統制報告書-第129期(2023/04/01-2024/03/31)
Japanese 21.7 KB
2024-06-28 08:21
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-28 08:19
Annual Report
有価証券報告書-第129期(2023/04/01-2024/03/31)
Japanese 1007.9 KB
2024-02-14 01:17
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-14 01:17
Quarterly Report
四半期報告書-第129期第3四半期(2023/10/01-2023/12/31)
Japanese 155.8 KB
2023-11-13 01:54
Report Publication Announcement
確認書
Japanese 8.0 KB
2023-11-13 01:53
Quarterly Report
四半期報告書-第129期第2四半期(2023/07/01-2023/09/30)
Japanese 187.2 KB

Automate Your Workflow. Get a real-time feed of all WAKAMOTO PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for WAKAMOTO PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.